Nexus Oncology

Edinburgh, United Kingdom Founded: 1999 • Age: 27 yrs Acquired By Chiltern
Specialist oncology clinical research services for drug trials were provided.

About Nexus Oncology

Nexus Oncology is a Healthcare company based in Edinburgh (United Kingdom) founded in 1999, and was acquired by Chiltern in January 2012. Specialist oncology clinical research services for drug trials were provided. Nexus Oncology offers products and services including Roundtable Discussions, Video Clips, and Conferences. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service.

Company details

Nexus Oncology was founded in 1999 in Edinburgh, United Kingdom, as a contract research organization focused on the oncology sector. Clinical research services were delivered to biopharmaceutical companies for the development of cancer treatments. Drug development programs were designed and implemented across phase I, II, and III oncology trials. The company was acquired by Ockham in February 2012.

Key Metrics

Products & Services of Nexus Oncology

Nexus Oncology offers a comprehensive portfolio of products and services, including Roundtable Discussions, Video Clips, and Conferences.

Roundtable Discussions
Educational Program

Connects experts with oncologists for clinical data updates.

Video Clips
On-Demand Updates

Delivers short videos on latest clinical data via text messages.

Conferences
Continuing Education

Hosts events for advancing oncology knowledge and practices.

Investors in Nexus Oncology

Nexus Oncology has secured backing from 1 investor. Prominent investors backing the company include Chiltern.

All
InvestorDescriptionFounded YearDomainLocation
Full-service oncology CRO operations are conducted globally.
1986ockham.comSacramento, United States
Premium access

Investor details for Nexus Oncology

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Nexus Oncology

2 dated milestones of Nexus Oncology across 13 years, from founding to its latest funding, stage changes and deals.

  1. Founded Nexus Oncology is founded.
  2. Exit Acquired by Chiltern.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Nexus Oncology

Nexus Oncology was founded in 1999.

Nexus Oncology is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.

Nexus Oncology was founded in 1999 in Edinburgh, United Kingdom, as a contract research organization focused on the oncology sector. Clinical research services were delivered to biopharmaceutical companies for the development of cancer treatments. Drug development programs were designed and implemented across phase I, II, and III oncology trials. The company was acquired by Ockham in February 2012.

Nexus Oncology offers Roundtable Discussions, Video Clips, and Conferences.

Nexus Oncology has 1 investor. Key investors include Chiltern.

Yes. Nexus Oncology was acquired by Chiltern in January 2012.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available